FDA approves AMI's Gastromark agent

Article

The Food and Drug Administration has approved a new drug applicationfor Gastromark, a gastrointestinal MRI contrast agent developedby Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagneticoral contrast agent that has been licensed to

The Food and Drug Administration has approved a new drug application

for Gastromark, a gastrointestinal MRI contrast agent developed

by Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagnetic

oral contrast agent that has been licensed to Mallinckrodt Medical

of St. Louis. The agent is marketed in Western Europe by Guerbet

under the trade name Lumirem. Gastromark will be priced at about

$25 per 300 mL, according to Jerome Goldstein, president and CEO

of Advanced Magnetics. Either 600 or 900 mL will likely be administered,

bringing the total cost to between $50 and $75 per patient.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.